메뉴 건너뛰기




Volumn 35, Issue 18, 2017, Pages 2062-2081

Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: A Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

EID: 85021713283     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.7257     Document Type: Review
Times cited : (176)

References (128)
  • 1
    • 33745915883 scopus 로고    scopus 로고
    • Canadian Cancer Society: Canadian Cancer Statistics 2015. http://www.cancer.ca/en/cancerinformation/cancer-101/canadian-cancer-statisticspublication/? region5on
    • Canadian Cancer Statistics 2015
  • 2
    • 84918815964 scopus 로고    scopus 로고
    • Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
    • Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015
    • (2015) Int J Cancer , vol.136 , pp. E359-E386
    • Ferlay, J.1    Soerjomataram, I.2    Dikshit, R.3
  • 3
    • 50549121134 scopus 로고
    • The distribution of secondary growths in cancer of the breast
    • Paget S: The distribution of secondary growths in cancer of the breast. [reproduced from The Lancet 133:571-573, 1889]
    • (1889) Reproduced from the Lancet , vol.133 , pp. 571-573
    • Paget, S.1
  • 5
    • 84892813877 scopus 로고    scopus 로고
    • Does estrogen play a role in response to adjuvant bonetargeted therapies?
    • Russell K, Amir E, Paterson A, et al: Does estrogen play a role in response to adjuvant bonetargeted therapies? J Bone Oncol 2:167-173, 2013
    • (2013) J Bone Oncol , vol.2 , pp. 167-173
    • Russell, K.1    Amir, E.2    Paterson, A.3
  • 6
    • 84933050150 scopus 로고    scopus 로고
    • Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting
    • Jacobs C, Amir E, Paterson A, et al: Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting. J Bone Oncol 4:54-58, 2015
    • (2015) J Bone Oncol , vol.4 , pp. 54-58
    • Jacobs, C.1    Amir, E.2    Paterson, A.3
  • 7
    • 60549097419 scopus 로고    scopus 로고
    • Endocrine therapy plus zoledronic acid in premenopausal breast cancer
    • Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
    • (2009) N Engl J Med , vol.360 , pp. 679-691
    • Gnant, M.1    Mlineritsch, B.2    Schippinger, W.3
  • 8
    • 66249142333 scopus 로고    scopus 로고
    • Erratum
    • [Erratum: N Engl J Med 360:2379, 2009]
    • (2009) N Engl J Med , vol.360 , pp. 2379
  • 9
    • 79959565208 scopus 로고    scopus 로고
    • Adjuvant endocrine therapy plus zoledronic acid in premenopausalwomen with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
    • Gnant M, Mlineritsch B, Stoeger H, et al: Adjuvant endocrine therapy plus zoledronic acid in premenopausalwomen with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631-641, 2011
    • (2011) Lancet Oncol , vol.12 , pp. 631-641
    • Gnant, M.1    Mlineritsch, B.2    Stoeger, H.3
  • 10
    • 84925337899 scopus 로고    scopus 로고
    • Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
    • Gnant M, Mlineritsch B, Stoeger H, et al: Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 26:313-320, 2015
    • (2015) Ann Oncol , vol.26 , pp. 313-320
    • Gnant, M.1    Mlineritsch, B.2    Stoeger, H.3
  • 11
    • 80054035939 scopus 로고    scopus 로고
    • Breast-cancer adjuvant therapy with zoledronic acid
    • Coleman RE, Marshall H, Cameron D, et al: Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405, 2011
    • (2011) N Engl J Med , vol.365 , pp. 1396-1405
    • Coleman, R.E.1    Marshall, H.2    Cameron, D.3
  • 12
    • 84905007644 scopus 로고    scopus 로고
    • Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
    • Coleman R, Cameron D, Dodwell D, et al: Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 15:997-1006, 2014
    • (2014) Lancet Oncol , vol.15 , pp. 997-1006
    • Coleman, R.1    Cameron, D.2    Dodwell, D.3
  • 13
    • 84944177030 scopus 로고    scopus 로고
    • Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. Lancet 386:1353-1361, 2015
    • (2015) Lancet , vol.386 , pp. 1353-1361
  • 14
    • 0031886868 scopus 로고    scopus 로고
    • Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: The role of practitioner feedback
    • Browman GP, Newman TE, Mohide EA, et al: Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: The role of practitioner feedback. J Clin Oncol 16:1226-1231, 1998
    • (1998) J Clin Oncol , vol.16 , pp. 1226-1231
    • Browman, G.P.1    Newman, T.E.2    Mohide, E.A.3
  • 15
    • 0028896975 scopus 로고
    • The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation
    • Browman GP, Levine MN, Mohide EA, et al: The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation. J Clin Oncol 13:502-512, 1995
    • (1995) J Clin Oncol , vol.13 , pp. 502-512
    • Browman, G.P.1    Levine, M.N.2    Mohide, E.A.3
  • 18
    • 84959879550 scopus 로고    scopus 로고
    • Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European panel
    • Hadji P, Coleman RE, Wilson C, et al: Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European panel. Ann Oncol 27:379-390, 2016
    • (2016) Ann Oncol , vol.27 , pp. 379-390
    • Hadji, P.1    Coleman, R.E.2    Wilson, C.3
  • 19
    • 0036682211 scopus 로고    scopus 로고
    • Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer
    • Powles T, Paterson S, Kanis JA, et al: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219-3224, 2002
    • (2002) J Clin Oncol , vol.20 , pp. 3219-3224
    • Powles, T.1    Paterson, S.2    Kanis, J.A.3
  • 20
    • 33744828376 scopus 로고    scopus 로고
    • Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
    • Powles T, Paterson A, McCloskey E, et al: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8:R13, 2006
    • (2006) Breast Cancer Res , vol.8 , pp. R13
    • Powles, T.1    Paterson, A.2    McCloskey, E.3
  • 21
    • 0038103008 scopus 로고    scopus 로고
    • Extended safety profile of oral clodronate after long-term use in primary breast cancer patients
    • Atula S, Powles T, Paterson A, et al: Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf 26:661-671, 2003
    • (2003) Drug Saf , vol.26 , pp. 661-671
    • Atula, S.1    Powles, T.2    Paterson, A.3
  • 22
    • 75149173381 scopus 로고    scopus 로고
    • Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer
    • McCloskey E, Paterson A, Kanis J, et al: Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur J Cancer 46:558-565, 2010
    • (2010) Eur J Cancer , vol.46 , pp. 558-565
    • McCloskey, E.1    Paterson, A.2    Kanis, J.3
  • 23
    • 0032491037 scopus 로고    scopus 로고
    • Reduction in new metastases in breast cancer with adjuvant clodronate treatment
    • Diel IJ, Solomayer EF, Costa SD, et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363, 1998
    • (1998) N Engl J Med , vol.339 , pp. 357-363
    • Diel, I.J.1    Solomayer, E.F.2    Costa, S.D.3
  • 24
    • 56749165071 scopus 로고    scopus 로고
    • Adjuvant oral clodronate improves the overall survival of primary breast cancer patientswithmicrometastases to the bone marrow: A long-term follow-up
    • Diel IJ, Jaschke A, Solomayer EF, et al: Adjuvant oral clodronate improves the overall survival of primary breast cancer patientswithmicrometastases to the bone marrow: A long-term follow-up. Ann Oncol 19:2007-2011, 2008
    • (2008) Ann Oncol , vol.19 , pp. 2007-2011
    • Diel, I.J.1    Jaschke, A.2    Solomayer, E.F.3
  • 25
    • 0035148170 scopus 로고    scopus 로고
    • Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial
    • Saarto T, Blomqvist C, Virkkunen P, et al: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19:10-17, 2001
    • (2001) J Clin Oncol , vol.19 , pp. 10-17
    • Saarto, T.1    Blomqvist, C.2    Virkkunen, P.3
  • 26
    • 9444254706 scopus 로고    scopus 로고
    • Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients
    • Saarto T, Vehmanen L, Virkkunen P, et al: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43:650-656, 2004
    • (2004) Acta Oncol , vol.43 , pp. 650-656
    • Saarto, T.1    Vehmanen, L.2    Virkkunen, P.3
  • 27
    • 52049093463 scopus 로고    scopus 로고
    • Tenyear follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer
    • Saarto T, Vehmanen L, Blomqvist C, et al: Tenyear follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 26:4289-4295, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 4289-4295
    • Saarto, T.1    Vehmanen, L.2    Blomqvist, C.3
  • 28
    • 17644364397 scopus 로고    scopus 로고
    • Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer
    • Leppä S, Saarto T, Vehmanen L, et al: Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer. Breast Cancer Res Treat 90:117-125, 2005
    • (2005) Breast Cancer Res Treat , vol.90 , pp. 117-125
    • Leppä, S.1    Saarto, T.2    Vehmanen, L.3
  • 29
    • 84863109831 scopus 로고    scopus 로고
    • Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial
    • Paterson AH, Anderson SJ, Lembersky BC, et al: Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial. Lancet Oncol 13:734-742, 2012
    • (2012) Lancet Oncol , vol.13 , pp. 734-742
    • Paterson, A.H.1    Anderson, S.J.2    Lembersky, B.C.3
  • 30
    • 45149109989 scopus 로고    scopus 로고
    • Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: Indirect comparison of dose and schedule in DBCG trials 77, 82, and 89
    • Ejlertsen B, Mouridsen HT, Jensen MB: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: Indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. Acta Oncol 47:662-671, 2008
    • (2008) Acta Oncol , vol.47 , pp. 662-671
    • Ejlertsen, B.1    Mouridsen, H.T.2    Jensen, M.B.3
  • 31
    • 45149083364 scopus 로고    scopus 로고
    • Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
    • Kristensen B, Ejlertsen B, Mouridsen HT, et al: Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 47:740-746, 2008
    • (2008) Acta Oncol , vol.47 , pp. 740-746
    • Kristensen, B.1    Ejlertsen, B.2    Mouridsen, H.T.3
  • 32
    • 84892471140 scopus 로고    scopus 로고
    • German adjuvant intergroup node-positive study: A phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
    • Von Minckwitz G, Möbus V, Schneeweiss A, et al: German adjuvant intergroup node-positive study: A phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 31:3531-3539, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 3531-3539
    • Von Minckwitz, G.1    Möbus, V.2    Schneeweiss, A.3
  • 33
    • 79958182699 scopus 로고    scopus 로고
    • Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer
    • Coleman R, Woodward E, Brown J, et al: Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat 127:429-438, 2011
    • (2011) Breast Cancer Res Treat , vol.127 , pp. 429-438
    • Coleman, R.1    Woodward, E.2    Brown, J.3
  • 34
    • 84890058802 scopus 로고    scopus 로고
    • Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: An adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04)
    • Rathbone EJ, Brown JE, Marshall HC, et al: Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: An adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol 31:2685-2691, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 2685-2691
    • Rathbone, E.J.1    Brown, J.E.2    Marshall, H.C.3
  • 35
    • 84910665810 scopus 로고    scopus 로고
    • Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxanebased chemotherapy for primary breast cancer-The phase III NATAN study (GBG 36/ABCSG XX)
    • S5-05
    • Von Minckwitz G, Rezai M, Eidtmann H, et al: Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxanebased chemotherapy for primary breast cancer-The phase III NATAN study (GBG 36/ABCSG XX). Cancer Res 73, 2013 (abstr S5-05)
    • (2013) Cancer Res , vol.73
    • Von Minckwitz, G.1    Rezai, M.2    Eidtmann, H.3
  • 37
    • 84885358543 scopus 로고    scopus 로고
    • Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: Results of a prospective clinical trial
    • Banys M, Solomayer EF, Gebauer G, et al: Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: Results of a prospective clinical trial. BMC Cancer 13:480, 2013
    • (2013) BMC Cancer , vol.13 , pp. 480
    • Banys, M.1    Solomayer, E.F.2    Gebauer, G.3
  • 38
    • 84864317505 scopus 로고    scopus 로고
    • Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients
    • Solomayer EF, Gebauer G, Hirnle P, et al: Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 23:2271-2277, 2012
    • (2012) Ann Oncol , vol.23 , pp. 2271-2277
    • Solomayer, E.F.1    Gebauer, G.2    Hirnle, P.3
  • 39
    • 77952305169 scopus 로고    scopus 로고
    • Effect of zoledronic acid on disseminated tumour cells in womenwith locally advanced breast cancer: An open label, randomised, phase 2 trial
    • Aft R, Naughton M, Trinkaus K, et al: Effect of zoledronic acid on disseminated tumour cells in womenwith locally advanced breast cancer: An open label, randomised, phase 2 trial. Lancet Oncol 11:421-428, 2010
    • (2010) Lancet Oncol , vol.11 , pp. 421-428
    • Aft, R.1    Naughton, M.2    Trinkaus, K.3
  • 40
    • 84862986485 scopus 로고    scopus 로고
    • Effect of (neo) adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer
    • Aft RL, Naughton M, Trinkaus K, et al: Effect of (neo) adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer. Br J Cancer 107:7-11, 2012
    • (2012) Br J Cancer , vol.107 , pp. 7-11
    • Aft, R.L.1    Naughton, M.2    Trinkaus, K.3
  • 41
    • 33947524592 scopus 로고    scopus 로고
    • Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
    • Brufsky A, Harker WG, Beck JT, et al: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829-836, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 829-836
    • Brufsky, A.1    Harker, W.G.2    Beck, J.T.3
  • 42
    • 67649804881 scopus 로고    scopus 로고
    • Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results
    • Brufsky AM, Bosserman LD, Caradonna RR, et al: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85, 2009
    • (2009) Clin Breast Cancer , vol.9 , pp. 77-85
    • Brufsky, A.M.1    Bosserman, L.D.2    Caradonna, R.R.3
  • 43
    • 84857370664 scopus 로고    scopus 로고
    • Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole
    • Brufsky AM, Harker WG, Beck JT, et al: Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118:1192-1201, 2012
    • (2012) Cancer , vol.118 , pp. 1192-1201
    • Brufsky, A.M.1    Harker, W.G.2    Beck, J.T.3
  • 44
    • 77954580167 scopus 로고    scopus 로고
    • Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
    • Eidtmann H, De Boer R, Bundred N, et al: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21:2188-2194, 2010
    • (2010) Ann Oncol , vol.21 , pp. 2188-2194
    • Eidtmann, H.1    De Boer, R.2    Bundred, N.3
  • 45
    • 84873825231 scopus 로고    scopus 로고
    • Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results
    • Coleman R, De Boer R, Eidtmann H, et al: Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results. Ann Oncol 24:398-405, 2013
    • (2013) Ann Oncol , vol.24 , pp. 398-405
    • Coleman, R.1    De Boer, R.2    Eidtmann, H.3
  • 46
    • 84862926420 scopus 로고    scopus 로고
    • Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial
    • Llombart A, Frassoldati A, Paija O, et al: Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12:40-48, 2012
    • (2012) Clin Breast Cancer , vol.12 , pp. 40-48
    • Llombart, A.1    Frassoldati, A.2    Paija, O.3
  • 47
    • 79551534714 scopus 로고    scopus 로고
    • Does short-term, intravenous, low dose clodronate, administered with adjuvant chemotherapy for premenopausal breast cancer reduce bone loss in the first year in patients?
    • 270
    • Bryce CJ, Prior J, Sill K, et al: Does short-term, intravenous, low dose clodronate, administered with adjuvant chemotherapy for premenopausal breast cancer reduce bone loss in the first year in patients? Proc Am Soc Clin Oncol 21:68a, 2002 (abstr 270)
    • (2002) Proc Am Soc Clin Oncol , vol.21 , pp. 68a
    • Bryce, C.J.1    Prior, J.2    Sill, K.3
  • 48
    • 58149166777 scopus 로고    scopus 로고
    • Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer
    • Lester JE, Dodwell D, Purohit OP, et al: Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342, 2008
    • (2008) Clin Cancer Res , vol.14 , pp. 6336-6342
    • Lester, J.E.1    Dodwell, D.2    Purohit, O.P.3
  • 49
    • 84877084313 scopus 로고    scopus 로고
    • Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial
    • Lester JE, Dodwell D, Brown JE, et al: Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial. J Bone Oncol 1:57-62, 2012
    • (2012) J Bone Oncol , vol.1 , pp. 57-62
    • Lester, J.E.1    Dodwell, D.2    Brown, J.E.3
  • 50
    • 61449227421 scopus 로고    scopus 로고
    • Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer
    • Hines SL, Mincey BA, Sloan JA, et al: Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 27:1047-1053, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 1047-1053
    • Hines, S.L.1    Mincey, B.A.2    Sloan, J.A.3
  • 51
    • 77956636088 scopus 로고    scopus 로고
    • Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: Results from the ARBI prospective clinical trial
    • Markopoulos C, Tzoracoleftherakis E, Polychronis A, et al: Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: Results from the ARBI prospective clinical trial. Breast Cancer Res 12:R24, 2010
    • (2010) Breast Cancer Res , vol.12 , pp. R24
    • Markopoulos, C.1    Tzoracoleftherakis, E.2    Polychronis, A.3
  • 52
    • 77949900992 scopus 로고    scopus 로고
    • Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial
    • Van Poznak C, Hannon RA, Mackey JR, et al: Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial. J Clin Oncol 28:967-975, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 967-975
    • Van Poznak, C.1    Hannon, R.A.2    Mackey, J.R.3
  • 53
    • 84878038828 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer-A randomized biomarker pilot study
    • Winter MC, Wilson C, Syddall SP, et al: Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer-A randomized biomarker pilot study. Clin Cancer Res 19:2755-2765, 2013
    • (2013) Clin Cancer Res , vol.19 , pp. 2755-2765
    • Winter, M.C.1    Wilson, C.2    Syddall, S.P.3
  • 54
    • 84864928163 scopus 로고    scopus 로고
    • Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: The randomized phase 3 HOBOE study
    • Nuzzo F, Gallo C, Lastoria S, et al: Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: The randomized phase 3 HOBOE study. Ann Oncol 23:2027-2033, 2012
    • (2012) Ann Oncol , vol.23 , pp. 2027-2033
    • Nuzzo, F.1    Gallo, C.2    Lastoria, S.3
  • 55
    • 78651104412 scopus 로고    scopus 로고
    • Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: A phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)
    • Kim JE, Ahn J-H, Jung KH, et al: Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: A phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat 125:99-106, 2011
    • (2011) Breast Cancer Res Treat , vol.125 , pp. 99-106
    • Kim, J.E.1    Ahn, J.-H.2    Jung, K.H.3
  • 56
    • 70349571180 scopus 로고    scopus 로고
    • Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
    • Hines SL, Mincey B, Dentchev T, et al: Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 117:603-609, 2009
    • (2009) Breast Cancer Res Treat , vol.117 , pp. 603-609
    • Hines, S.L.1    Mincey, B.2    Dentchev, T.3
  • 57
    • 84937518556 scopus 로고    scopus 로고
    • 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial
    • Wagner-Johnston ND, Sloan JA, Liu H, et al:5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-2543, 2015
    • (2015) Cancer , vol.121 , pp. 2537-2543
    • Wagner-Johnston, N.D.1    Sloan, J.A.2    Liu, H.3
  • 58
    • 85021717367 scopus 로고    scopus 로고
    • Effect of zoledronic acid on bone density of premenopausal breast cancer patients under (neo) adjuvant chemotherapy: The ProBone I study (German)
    • Hadji P, Kauka A, Bauer T, et al: Effect of zoledronic acid on bone density of premenopausal breast cancer patients under (neo) adjuvant chemotherapy: The ProBone I study (German). Senologie - Zeitschrift fü r Mammadiagnostik und -therapie 9:A58, 2012
    • (2012) Senologie - Zeitschrift Fü R Mammadiagnostik und -therapie , vol.9 , pp. A58
    • Hadji, P.1    Kauka, A.2    Bauer, T.3
  • 59
    • 84897023705 scopus 로고    scopus 로고
    • Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR1 breast cancer: The ProBONE II study
    • Hadji P, Kauka A, Ziller M, et al: Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR1 breast cancer: The ProBONE II study. Osteoporos Int 25:1369-1378, 2014
    • (2014) Osteoporos Int , vol.25 , pp. 1369-1378
    • Hadji, P.1    Kauka, A.2    Ziller, M.3
  • 60
    • 84896542372 scopus 로고    scopus 로고
    • Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: The ProBONE II study
    • Hadji P, Kauka A, Ziller M, et al: Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: The ProBONE II study. Breast Cancer Res Treat 144:343-351, 2014
    • (2014) Breast Cancer Res Treat , vol.144 , pp. 343-351
    • Hadji, P.1    Kauka, A.2    Ziller, M.3
  • 61
    • 82955165853 scopus 로고    scopus 로고
    • The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: A prospective, randomized, phase II trial
    • Safra T, Bernstein-Molho R, Greenberg J, et al: The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: A prospective, randomized, phase II trial. Oncology 81:298-305, 2011
    • (2011) Oncology , vol.81 , pp. 298-305
    • Safra, T.1    Bernstein-Molho, R.2    Greenberg, J.3
  • 62
    • 84922349261 scopus 로고    scopus 로고
    • SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery
    • 558
    • Gralow J, Barlow WE, Paterson A H G, et al: SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery. J Clin Oncol 32, 2014 (abstr 558)
    • (2014) J Clin Oncol , pp. 32
    • Gralow, J.1    Barlow, W.E.2    Paterson, A.H.G.3
  • 63
    • 84945570878 scopus 로고    scopus 로고
    • Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRGOncology Study S0307
    • 503
    • Gralow J, Barlow WE, Paterson A H G, et al: Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRGOncology Study S0307. J Clin Oncol 33, 2015 (abstr 503)
    • (2015) J Clin Oncol , pp. 33
    • Gralow, J.1    Barlow, W.E.2    Paterson, A.H.G.3
  • 64
    • 84938751180 scopus 로고    scopus 로고
    • Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial
    • Gnant M, Pfeiler G, Dubsky PC, et al: Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433-443, 2015
    • (2015) Lancet , vol.386 , pp. 433-443
    • Gnant, M.1    Pfeiler, G.2    Dubsky, P.C.3
  • 65
    • 84984825009 scopus 로고    scopus 로고
    • The impact of adjuvant denosumab on disease-free survival: Results from 3, 425 postmenopausal patients of the ABCSG-18 trial
    • S2-02
    • Gnant M, Pfeiler G, Dubsky PC, et al: The impact of adjuvant denosumab on disease-free survival: Results from 3, 425 postmenopausal patients of the ABCSG-18 trial. Cancer Res 76, 2016 (abstr S2-02)
    • (2016) Cancer Res , pp. 76
    • Gnant, M.1    Pfeiler, G.2    Dubsky, P.C.3
  • 67
    • 0033870883 scopus 로고    scopus 로고
    • Adjuvant clodronate therapy in patients with locally advanced breast cancer-Long term results of a double blind randomized trial
    • Mardiak J, Bohunickćy L, Chovanec J, et al: Adjuvant clodronate therapy in patients with locally advanced breast cancer-Long term results of a double blind randomized trial. Neoplasma 47:177-180, 2000
    • (2000) Neoplasma , vol.47 , pp. 177-180
    • Mardiak, J.1    Bohunickćy, L.2    Chovanec, J.3
  • 68
    • 84955488881 scopus 로고    scopus 로고
    • Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE study)
    • Hasegawa Y, Tanino H, Horiguchi J, et al: Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE study). PLoS One 10:e0143643, 2015
    • (2015) PLoS One , vol.10 , pp. e0143643
    • Hasegawa, Y.1    Tanino, H.2    Horiguchi, J.3
  • 69
    • 85021710223 scopus 로고    scopus 로고
    • Disease-free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer (JONIE-1 study)
    • PD3-7
    • Miura D, Hasegawa Y, Horiguchi J, et al: Disease-free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer (JONIE-1 study). Cancer Res 73, 2013 (abstr PD3-7)
    • (2013) Cancer Res , pp. 73
    • Miura, D.1    Hasegawa, Y.2    Horiguchi, J.3
  • 70
    • 85021714934 scopus 로고    scopus 로고
    • A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer
    • PD07-05
    • Hasegawa Y, Kohno N, Horiguchi J, et al: A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer. Cancer Res 72:2012 (abstr PD07-05)
    • Cancer Res , vol.72 , pp. 2012
    • Hasegawa, Y.1    Kohno, N.2    Horiguchi, J.3
  • 71
    • 84883208612 scopus 로고    scopus 로고
    • A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer
    • 1029
    • Horiguchi J, Hasegawa Y, Miura D, et al: A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer. J Clin Oncol 31, 2013 (abstr 1029)
    • (2013) J Clin Oncol , pp. 31
    • Horiguchi, J.1    Hasegawa, Y.2    Miura, D.3
  • 72
    • 85021750140 scopus 로고    scopus 로고
    • Zoledronic acid combined with adjuvant tamoxifen with or without ovarian function suppression in premenopausal early breast cancer patients
    • P5-15-04
    • El-Ibrashi MM, El-Sadda WM, Abdel-Halim II, et al: Zoledronic acid combined with adjuvant tamoxifen with or without ovarian function suppression in premenopausal early breast cancer patients. Cancer Res 76, 2016 (abstr P5-15-04)
    • (2016) Cancer Res , pp. 76
    • El-Ibrashi, M.M.1    El-Sadda, W.M.2    Abdel-Halim, I.I.3
  • 73
    • 84863716562 scopus 로고    scopus 로고
    • Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results
    • Takahashi S, Iwase T, Kohno N, et al: Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat 133:685-693, 2012
    • (2012) Breast Cancer Res Treat , vol.133 , pp. 685-693
    • Takahashi, S.1    Iwase, T.2    Kohno, N.3
  • 74
    • 85021731406 scopus 로고    scopus 로고
    • Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 36-month results
    • e20510
    • Takahashi S, Iwase T, Kohno N, et al: Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 36-month results. J Clin Oncol 31, 2013 (abstr e20510)
    • (2013) J Clin Oncol , pp. 31
    • Takahashi, S.1    Iwase, T.2    Kohno, N.3
  • 75
    • 85021701005 scopus 로고    scopus 로고
    • Assessment of bisphosphonates use as adjuvant therapy in breast cancer
    • 304p
    • Abu-Taleb FM, El-Zawahry HM, Zekri ZK, et al: Assessment of bisphosphonates use as adjuvant therapy in breast cancer. Ann Oncol 25: iv101-iv102, 2014 (abstr 304p)
    • (2014) Ann Oncol , vol.25 , pp. iv101-iv102
    • Abu-Taleb, F.M.1    El-Zawahry, H.M.2    Zekri, Z.K.3
  • 76
    • 85032590769 scopus 로고    scopus 로고
    • Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): A global, placebocontrolled, randomized, double-blind, phase 3 clinical trial
    • OT2-6-02
    • Goss PE, Barrios CH, Chan A, et al: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): A global, placebocontrolled, randomized, double-blind, phase 3 clinical trial. Cancer Res 73, 2013 (abstr OT2-6-02)
    • (2013) Cancer Res , pp. 73
    • Goss, P.E.1    Barrios, C.H.2    Chan, A.3
  • 78
    • 0027478423 scopus 로고
    • Meta-analysis of the literature or of individual patient data: Is there a difference?
    • Stewart LA, Parmar MK: Meta-analysis of the literature or of individual patient data: Is there a difference? Lancet 341:418-422, 1993
    • (1993) Lancet , vol.341 , pp. 418-422
    • Stewart, L.A.1    Parmar, M.K.2
  • 79
    • 85021746677 scopus 로고    scopus 로고
    • Netherlands Cancer Institute: Scientific annual report 2014. http://www.nki.nl/media/1388517/scientific %20annual%20report%202014%20LR.pdf
    • Scientific Annual Report 2014
  • 80
    • 84873393857 scopus 로고    scopus 로고
    • Participation in the SUCCESS-A trial improves intensity and quality of care for patients with primary breast cancer
    • Andergassen U, Kasprowicz NS, Hepp P, et al: Participation in the SUCCESS-A trial improves intensity and quality of care for patients with primary breast cancer. Geburtshilfe Frauenheilkd 73:63-69, 2013
    • (2013) Geburtshilfe Frauenheilkd , vol.73 , pp. 63-69
    • Andergassen, U.1    Kasprowicz, N.S.2    Hepp, P.3
  • 81
    • 85021772716 scopus 로고    scopus 로고
    • Prevalence of circulating tumor cells (CTCs) after five years of zoledronate treatment in the adjuvant SUCCESS-A study
    • P4-11-21
    • Rack B, Fasching PA, Haberle L, et al: Prevalence of circulating tumor cells (CTCs) after five years of zoledronate treatment in the adjuvant SUCCESS-A study. Cancer Res 75, 2015 (abstr P4-11-21)
    • (2015) Cancer Res , pp. 75
    • Rack, B.1    Fasching, P.A.2    Haberle, L.3
  • 82
    • 84865016897 scopus 로고    scopus 로고
    • Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review
    • Varun BR, Sivakumar TT, Nair BJ, et al: Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review. J Oral Maxillofac Pathol 16:210-214, 2012
    • (2012) J Oral Maxillofac Pathol , vol.16 , pp. 210-214
    • Varun, B.R.1    Sivakumar, T.T.2    Nair, B.J.3
  • 83
    • 84919691137 scopus 로고    scopus 로고
    • Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis
    • Inderjeeth CA, Glendenning P, Ratnagobal S, et al: Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis. Int J Womens Health 7:7-17, 2014
    • (2014) Int J Womens Health , vol.7 , pp. 7-17
    • Inderjeeth, C.A.1    Glendenning, P.2    Ratnagobal, S.3
  • 84
    • 80054862345 scopus 로고    scopus 로고
    • Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials
    • Lee YH, Song GG: Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med 26:340-347, 2011
    • (2011) Korean J Intern Med , vol.26 , pp. 340-347
    • Lee, Y.H.1    Song, G.G.2
  • 85
    • 5444243800 scopus 로고    scopus 로고
    • Safety of intravenous and oral bisphosphonates and compliance with dosing regimens
    • Conte P, Guarneri V: Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9:28-37, 2004(suppl 4)
    • (2004) Oncologist , vol.9 , pp. 28-37
    • Conte, P.1    Guarneri, V.2
  • 86
    • 85021760639 scopus 로고    scopus 로고
    • Clodronate
    • August
    • Cancer Care Ontario: Clodronate. Drug monograph. CCO formulary, August 2015. https://www.cancercare.on. ca/CCO-DrugFormulary/Pages/DfPdfContent.aspx?itemId593927
    • (2015) Drug Monograph. CCO Formulary
  • 87
    • 84875718985 scopus 로고    scopus 로고
    • The incidence of acute anterior uveitis after intravenous zoledronate
    • Patel DV, Horne A, House M, et al: The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology 120:773-776, 2013
    • (2013) Ophthalmology , vol.120 , pp. 773-776
    • Patel, D.V.1    Horne, A.2    House, M.3
  • 88
    • 84861148411 scopus 로고    scopus 로고
    • Inflammatory ocular adverse events with the use of oral bisphosphonates: A retrospective cohort study
    • Etminan M, Forooghian F, Maberley D: Inflammatory ocular adverse events with the use of oral bisphosphonates: A retrospective cohort study. CMAJ 184:E431-E434, 2012
    • (2012) CMAJ , vol.184 , pp. E431-E434
    • Etminan, M.1    Forooghian, F.2    Maberley, D.3
  • 89
    • 33646863929 scopus 로고    scopus 로고
    • Management of the adverse effects associated with intravenous bisphosphonates
    • Tanvetyanon T, Stiff PJ: Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17:897-907, 2006
    • (2006) Ann Oncol , vol.17 , pp. 897-907
    • Tanvetyanon, T.1    Stiff, P.J.2
  • 90
    • 84861670957 scopus 로고    scopus 로고
    • Antiresorptive treatment options and bone health in cancer patients-Safety profiles and clinical considerations
    • Hadji P, Aapro M, Costa L, et al: Antiresorptive treatment options and bone health in cancer patients-Safety profiles and clinical considerations. Cancer Treat Rev 38:815-824, 2012
    • (2012) Cancer Treat Rev , vol.38 , pp. 815-824
    • Hadji, P.1    Aapro, M.2    Costa, L.3
  • 91
    • 78649680817 scopus 로고    scopus 로고
    • 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary
    • Papaioannou A, Morin S, Cheung AM, et al:2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. CMAJ 182:1864-1873, 2010
    • (2010) CMAJ , vol.182 , pp. 1864-1873
    • Papaioannou, A.1    Morin, S.2    Cheung, A.M.3
  • 92
    • 85021738111 scopus 로고    scopus 로고
    • Osteoporosis: Clinical guideline for prevention and treatment
    • Updated January
    • National Osteoporosis Guideline Group: Osteoporosis: Clinical guideline for prevention and treatment. Executive summary. Updated January 2016. www.shef.ac.uk/NOGG/NOGG-Executive-Summary.pdf
    • (2016) Executive Summary
  • 93
    • 84919418591 scopus 로고    scopus 로고
    • Clinician's guide to prevention and treatment of osteoporosis
    • Cosman F, De Beur SJ, LeBoff MS, et al: Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359-2381, 2014
    • (2014) Osteoporos Int , vol.25 , pp. 2359-2381
    • Cosman, F.1    De Beur, S.J.2    LeBoff, M.S.3
  • 94
    • 85021699321 scopus 로고    scopus 로고
    • Erratum
    • [Erratum: Osteoporos Int 26:2045-2047, 2015]
    • (2015) Osteoporos Int , vol.26 , pp. 2045-2047
  • 95
    • 84969760966 scopus 로고    scopus 로고
    • Postmenopausal osteoporosis
    • Black DM, Rosen CJ: Postmenopausal osteoporosis. N Engl J Med 374:254-262, 2016
    • (2016) N Engl J Med , vol.374 , pp. 254-262
    • Black, D.M.1    Rosen, C.J.2
  • 97
    • 84976389243 scopus 로고    scopus 로고
    • Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American Society of Clinical Oncology endorsement of Cancer Care Ontario guideline recommendations
    • Henry NL, Somerfield MR, Abramson VG, et al: Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American Society of Clinical Oncology endorsement of Cancer Care Ontario guideline recommendations. J Clin Oncol 34:2303-2311, 2016
    • (2016) J Clin Oncol , vol.34 , pp. 2303-2311
    • Henry, N.L.1    Somerfield, M.R.2    Abramson, V.G.3
  • 98
    • 25444477545 scopus 로고    scopus 로고
    • Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis
    • Cramer JA, Amonkar MM, Hebborn A, et al: Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. CurrMed ResOpin 21:1453-1460, 2005
    • (2005) CurrMed ResOpin , vol.21 , pp. 1453-1460
    • Cramer, J.A.1    Amonkar, M.M.2    Hebborn, A.3
  • 99
    • 79551568488 scopus 로고    scopus 로고
    • Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study
    • Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 5132-5139
    • Stopeck, A.T.1    Lipton, A.2    Body, J.J.3
  • 100
    • 84867582660 scopus 로고    scopus 로고
    • Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
    • Lipton A, Fizazi K, Stopeck AT, et al: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082-3092, 2012
    • (2012) Eur J Cancer , vol.48 , pp. 3082-3092
    • Lipton, A.1    Fizazi, K.2    Stopeck, A.T.3
  • 101
    • 84882759793 scopus 로고    scopus 로고
    • Incidence and risk of denosumab-related hypocalcemia in cancer patients: A systematic review and pooled analysis of randomized controlled studies
    • Qi WX, Lin F, He AN, et al: Incidence and risk of denosumab-related hypocalcemia in cancer patients: A systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin 29:1067-1073, 2013
    • (2013) Curr Med Res Opin , vol.29 , pp. 1067-1073
    • Qi, W.X.1    Lin, F.2    He, A.N.3
  • 103
    • 84957609430 scopus 로고    scopus 로고
    • Managing osteoporosis in patients on longterm bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research
    • Adler RA, El-Hajj Fuleihan G, Bauer DC, et al: Managing osteoporosis in patients on longterm bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16-35, 2016
    • (2016) J Bone Miner Res , vol.31 , pp. 16-35
    • Adler, R.A.1    El-Hajj Fuleihan, G.2    Bauer, D.C.3
  • 104
    • 33750049947 scopus 로고    scopus 로고
    • Serum estradiol above the postmenopausal level after chemotherapy-induced amenorrhea in breast cancer patients
    • Braverman SA, Sawhney H, Tendler A, et al: Serum estradiol above the postmenopausal level after chemotherapy-induced amenorrhea in breast cancer patients. Therapy 3:609-612, 2006
    • (2006) Therapy , vol.3 , pp. 609-612
    • Braverman, S.A.1    Sawhney, H.2    Tendler, A.3
  • 105
    • 0017190910 scopus 로고
    • Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women
    • Groom GV, Griffiths K: Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70:421-428, 1976
    • (1976) J Endocrinol , vol.70 , pp. 421-428
    • Groom, G.V.1    Griffiths, K.2
  • 106
    • 84919934170 scopus 로고    scopus 로고
    • Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus
    • Khan AA, Morrison A, Hanley DA, et al: Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J Bone Miner Res 30:3-23, 2015
    • (2015) J Bone Miner Res , vol.30 , pp. 3-23
    • Khan, A.A.1    Morrison, A.2    Hanley, D.A.3
  • 107
    • 84909619222 scopus 로고    scopus 로고
    • American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update
    • Ruggiero SL, Dodson TB, Fantasia J, et al: American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 72:1938-1956, 2014
    • (2014) J Oral Maxillofac Surg , vol.72 , pp. 1938-1956
    • Ruggiero, S.L.1    Dodson, T.B.2    Fantasia, J.3
  • 108
    • 82055162846 scopus 로고    scopus 로고
    • Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs
    • Hellstein JW, Adler RA, Edwards B, et al: Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142:1243-1251, 2011
    • (2011) J Am Dent Assoc , vol.142 , pp. 1243-1251
    • Hellstein, J.W.1    Adler, R.A.2    Edwards, B.3
  • 110
  • 115
    • 85021727302 scopus 로고    scopus 로고
    • April
    • Cancer Care Onatrio: ZOLE regimen. Zoledronic acid. CCO formulary, April 2016. https://www.cancercare.on. ca/CCO-DrugFormulary/Pages/DfPdfContent.aspx?itemId5325962
    • (2016) ZOLE Regimen. Zoledronic Acid. CCO Formulary
  • 116
    • 30744458738 scopus 로고    scopus 로고
    • Novartis Pharmaceuticals Corporation: Zometa (zoledronic acid). www.accessdata.fda.gov/drugsatfda-docs/label/2016/021223s034lbl.pdf
    • Zometa (zoledronic Acid)
  • 117
    • 85021771495 scopus 로고    scopus 로고
    • Apotex Corp: Zoledronic acid. http://medlibrary.org/lib/rx/meds/zoledronic-acid-15
    • Zoledronic Acid
  • 118
    • 84922155743 scopus 로고    scopus 로고
    • Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: What are the risks?
    • Clark EM, Durup D: Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: What are the risks? Ther Adv Musculoskelet Dis 7:11-16, 2015
    • (2015) Ther Adv Musculoskelet Dis , vol.7 , pp. 11-16
    • Clark, E.M.1    Durup, D.2
  • 119
    • 0037456760 scopus 로고    scopus 로고
    • Bisphosphonates and ocular inflammation
    • Fraunfelder FW, Fraunfelder FT: Bisphosphonates and ocular inflammation. N Engl J Med 348:1187-1188, 2003
    • (2003) N Engl J Med , vol.348 , pp. 1187-1188
    • Fraunfelder, F.W.1    Fraunfelder, F.T.2
  • 122
    • 84938740077 scopus 로고    scopus 로고
    • Hypocalcaemia in patients with metastatic bone disease treated with denosumab
    • Body J-J, Bone HG, De Boer RH, et al: Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer 51:1812-1821, 2015
    • (2015) Eur J Cancer , vol.51 , pp. 1812-1821
    • Body, J.-J.1    Bone, H.G.2    De Boer, R.H.3
  • 123
    • 69049083492 scopus 로고    scopus 로고
    • Denosumab for prevention of fractures in postmenopausal women with osteoporosis
    • Cummings SR, San Martin J, McClung MR, et al: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765, 2009
    • (2009) N Engl J Med , vol.361 , pp. 756-765
    • Cummings, S.R.1    San Martin, J.2    McClung, M.R.3
  • 125
    • 84873979722 scopus 로고    scopus 로고
    • Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: Cohort analysis using a national prescription database
    • Pazianas M, Clark EM, Eiken PA, et al: Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: Cohort analysis using a national prescription database. J Bone Miner Res 28:455-463, 2013
    • (2013) J Bone Miner Res , vol.28 , pp. 455-463
    • Pazianas, M.1    Clark, E.M.2    Eiken, P.A.3
  • 127
    • 34848887818 scopus 로고    scopus 로고
    • Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid
    • Brown JE, Ellis SP, Lester JE, et al: Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 13:5406-5410, 2007
    • (2007) Clin Cancer Res , vol.13 , pp. 5406-5410
    • Brown, J.E.1    Ellis, S.P.2    Lester, J.E.3
  • 128
    • 85021763391 scopus 로고    scopus 로고
    • Investigating denosumab as add-on neoadjuvant treatment for hormone receptornegative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX)
    • TPS635
    • Kummel S, Von Minckwitz G, Nekljudova V, et al: Investigating denosumab as add-on neoadjuvant treatment for hormone receptornegative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX). J Clin Oncol 34:2016 (abstr TPS635)
    • J Clin Oncol , vol.34 , pp. 2016
    • Kummel, S.1    Von Minckwitz, G.2    Nekljudova, V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.